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Background: In up to 30% of patients with ischemic stroke no definite etiology can be established. A significant
proportion of cryptogenic stroke cases may be due to non-stenosing atherosclerotic plaques or low grade carotid
artery stenosis not fulfilling common criteria for atherothrombotic stroke. The aim of the CAPIAS study is to
determine the frequency, characteristics, clinical and radiological long-term consequences of ipsilateral complicated
American Heart Association lesion type VI (AHA-LT VI) carotid artery plaques in patients with cryptogenic stroke.
Methods/Design: 300 patients (age >49 years) with unilateral DWI-positive lesions in the anterior circulation and
non- or moderately stenosing (<70% NASCET) internal carotid artery plaques will be enrolled in the prospective
multicenter study CAPIAS. Carotid plaque characteristics will be determined by high-resolution black-blood carotid
MRI at baseline and 12 month follow up. Primary outcome is the prevalence of complicated AHA-LT VI plaques in
cryptogenic stroke patients ipsilateral to the ischemic stroke compared to the contralateral side and to patients with
defined stroke etiology. Secondary outcomes include the association of AHA-LT VI plaques with the recurrence rates
of ischemic events up to 36 months, rates of new ischemic lesions on cerebral MRI (including clinically silent lesions)
after 12 months and the influence of specific AHA-LT VI plaque features on the progression of atherosclerotic
disease burden, on specific infarct patterns, biomarkers and aortic arch plaques.
Discussion: CAPIAS will provide important insights into the role of non-stenosing carotid artery plaques in
cryptogenic stroke. The results might have implications for our understanding of stroke mechanism, offer new
diagnostic options and provide the basis for the planning of targeted interventional studies.
Trial Registration: NCT01284933
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Ischemic stroke is one of the leading causes of disability
and death in industrialized countries [1]. Current etiologic
classification systems like TOAST (trial of Org 10172 in
Acute Stroke Treatment) [2] or A-S-C-O [3] assign stroke
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distribution, and reproduction in any mediumatherosclerosis (LAA), cardioembolism (CE), small vessel
disease (SVD) or stroke of other determined etiology.
However, in up to 30% of cases the etiology remains
unknown (cryptogenic stroke) even in well characterized
patients [4,5]. A review by Amarenco suggested that a
significant proportion of these cases may be due to non-
stenosing atherosclerotic plaques or low grade cervical
artery stenosis not fulfilling common criteria for athero-
thrombotic stroke [6].
Previous histopathological examinations have demon-
strated a role of plaque rupture in myocardial infarction
[7] as well as atherosclerotic stroke [8]. Plaque rupture
depends on plaque vulnerability rather than plaque size.
Plaques with a lipid rich necrotic core, a thin fibrousCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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have been shown to predispose to rupture and thrombo-
embolic complications [9-11]. Despite the obvious associ-
ation of plaque composition and its vulnerability, current
treatment algorithms for carotid artery atherosclerosis use
stenosis grade as decision criterion whereas plaque char-
acteristics are usually not considered [12,13].
High-resolution black-blood carotid magnetic resonance
imaging (carotid MRI) allows non-invasive characterization
of atherosclerotic plaques by the assessment of plaque size,
plaque composition, and plaque morphology with good cor-
relation to histopathology [14,15]. Complicated American
Heart Association lesion type (AHA-LT) VI plaques are
characterized by plaque surface rupture, luminal thrombosis
and intra-plaque hemorrhage [14]. Furthermore, progression
of atherosclerotic disease burden can be monitored non-
invasively [16,17].
Previous MR plaque imaging studies on patients with ca-
rotid artery stenosis have revealed an association between
the presence of complicated AHA-LT VI features and ische-
mic events in cross-sectional [18,19] and longitudinal stud-
ies [20,21]. However, most of these studies were performed
in patients with high grade stenosis [20,21] and mixed co-
horts of both asymptomatic and symptomatic patients
[18,22]. Furthermore, they used a broader definition of the
index event [19], and time between symptoms and carotid
plaque MRI was up to 3 months [23]. In a prospective pilot
study on 32 cryptogenic stroke patients with non-stenosing
carotid artery plaques we recently found a prevalence of
37% for complicated AHA-LT VI plaques ipsilateral to the
ischemic stroke compared to the contralateral side, where
no AHA-LT VI plaques were found (p = 0.001) [24]. These
findings suggest a possible causative role of complicated
AHA-LT VI plaques in patients with cryptogenic stroke.
We thus initiated the current prospective CAPIAS study
with the primary aim to determine the prevalence of com-
plicated AHA-LT VI plaques ipsilateral to an acute ische-
mic stroke in patients with a cryptogenic stroke. Secondary
outcome measures include the association of complicated
AHA-LT VI plaques with specific infarct patterns, bio-
markers and aortic arch plaques, the evaluation of recur-
rence rates of ischemic events up to 36 months and rates
of new ischemic lesions on cerebral MRI (including clinic-
ally silent lesions) after 12 months as well as the evaluation
of the influence of specific AHA-LT VI plaque features on
the progression of atherosclerotic disease burden.
Methods
Study design
CAPIAS is an observational hospital-based cohort study in
patients suffering from acute stroke conducted at three
University hospitals in Germany. The study was initiated in
February 2011 at the Interdisciplinary Stroke Center in
Munich (Ludwig-Maximilians-University) and subsequentlyextended to the Technical University Munich and the Uni-
versity of Freiburg. The centers use identical core protocols,
particularly with regard to the radiological requirements
and identical data collection methods using TeleForm
(Electric Paper GmbH, Lüneburg, Germany). The study has
been approved by each local ethics committee (project
016–10, 20.12.2010), is conducted according to the Declar-
ation of Helsinki and has been registered at the trial regis-
tration website clinicaltrials.gov (NCT01284933). Patient
insurance for the study was contracted (policy number 40-
958405-03029/390). No randomization and study-related
interventions are planned. Patients are treated following
current guidelines for the treatment of stroke [25].
Patient population - Inclusion and exclusion criteria
Patients of both genders older than 49 years presenting
with neurological symptoms compatible with an acute
unilateral anterior circulation infarct within the last seven
days are recruited through certified stroke units at the par-
ticipating centers. DWI positive lesions in the territory of
a single internal carotid artery (ICA) on cerebral MRI and
the presence of plaques with ≥ 2 mm thickness on one of
the carotid arteries as defined by ultrasound are required
for inclusion. Patients with high-grade carotid artery sten-
osis (≥70% NASCET) are excluded from the study as these
patients usually undergo immediate invasive treatment
(carotid endarterectomy or carotid artery stenting) follow-
ing current guidelines. Additional exclusion criteria in-
clude bilateral ischemic lesions and infarcts within the
posterior circulation. For detailed inclusion and exclusion
criteria see Table 1.
In our study “Cryptogenic stroke” is defined as a stroke
`of undetermined origin’ according to TOASTclassification,
which is equivalent to the absence of grade 1 pathology ac-
cording to A-S-C-O. Thus, patients with concurrent etiolo-
gies will be analyzed as a separate group. Patients with
cardioembolic stroke or small vessel disease represent the
negative control group and patients with large artery ath-
erosclerosis (50-69% stenosis) serve as positive control.
Primary outcome
The primary outcome of the CAPIAS study is the preva-
lence of complicated AHA-LT VI plaques ipsilateral to an
acute ischemic stroke in the territory of a single carotid ar-
tery in patients with a cryptogenic stroke. The analyses
will include a comparison of the prevalence of compli-
cated AHA-LT VI plaques ipsilateral versus contralateral
to the ischemic stroke and a comparison of complicated
AHA-LT VI plaques in patients with cryptogenic stroke as
compared to patients with defined stroke etiology.
Secondary outcomes
Secondary outcomes include the association of compli-
cated AHA-LT VI plaques with specific infarct patterns
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age > 49 years old • Primary referral to an outside hospital
• Acute ischemic stroke or transient ischemic attack (TIA) • DWI positive lesions outside the territory of a single internal carotid artery
• Neurological symptoms compatible with a stroke or TIA in the territory
of the internal carotid artery
• Surgical procedure within 24 hours preceding the MRI
• Onset of symptoms within the last 7 days • History of radiation to the neck area
• 1 or more acute ischemic lesion(s) visible on MR diffusion-weighted
imaging (DWI) in the territory of a single internal carotid artery
• Carotid artery stenosis ≥70% (NASCET) ipsilateral to the stroke or
TIA as defined by ultrasound (systolic peak flow velocity≥ 300 cm/s)
• Presence of carotid artery plaques in the ipsi- or contra-lateral carotid
artery as defined by ultrasound (plaque thickness at least 2 mm; located
within 1 cm proximal or distal to the carotid bifurcation)
• Creatinine levels > 2 times the upper limit of the standard range of
the respective laboratory within the last 30 days prior to MRI and
Renal clearance < 30 ml/minute
• Written informed consent • Standard contra-indications for MRI
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nar lesions), with aortic arch plaques as determined by
transoesophageal echocardiography or computed tomog-
raphy angiography (CTA) and their association with bio-
markers derived from serum and plasma. Furthermore, we
will evaluate the recurrence rate of ischemic events and
the rate of new ischemic lesions on brain MRI in patients
with complicated AHA-LT VI plaques after twelve months
follow up. In addition, we will investigate whether specific
features of complicated AHA-LT VI plaques, such as
intraplaque hemorrhage and thin or ruptured fibrous cap
are associated with an increased progression rate of ath-
erosclerotic disease burden after twelve months.
Recurrent ischemic events include cerebrovascular and
cardiovascular events. Cerebrovascular events are de-
fined either clinically (TIA, amaurosis fugax or stroke),
by brain MRI alone (new ischemic lesion on brain MRI)
or on the combined assessment of clinical findings and
brain MRI. Furthermore, the most likely cause of the re-
current cerebrovascular event is classified according to
the ASCO and TOAST classifications. Unilateral events
in the anterior circulation will be included in the final
analysis to estimate the risk of recurrent events in pa-
tients with AHA-LT VI plaques. Recurrent ischemic
events in other territories, bilateral events and cardiovas-
cular events (myocardial infarction, vascular death) are
recorded during follow-up to evaluate if patients with
complicated AHA-LT VI plaques have a higher overall
atherosclerotic disease burden.
Assessment
All patients included into the study are interviewed and
examined within 7 days after stroke onset. Assessment
at 3, 24 and 36 months follow up is performed using a
structured telephone interview conducted centrally by
the coordinating center (LMU Munich). Twelve month
follow up consists of a clinical examination by a stroke
neurologist, blood investigations as well as repeated ca-
rotid and brain MRI. Table 2 gives a detailed schedule ofplanned assessments and time points. In cases where no
contact with the patient can be established, information
will be obtained from the Residents’ Registration Office.
Clinical and neuropsychological assessment
Information about demographics, living situation, func-
tional outcome, lifestyle habits, health and family history
as well as medication before stroke are provided by the pa-
tient or the next of kin. Cardiovascular Risk Factors are
defined according to current guidelines [26]. Cognitive
function is investigated using the Mini Mental State
Examination (MMSE) [27] and the Montreal Cognitive
Assessment (MoCA) [28]. The Informant Questionnaire
on Cognitive Decline in the Elderly (IQCODE) [29] will be
performed in subjects scoring below 27 in the MoCA.
Clinical examination consists of anthropometric measures
and a standardized neurological examination. Stroke se-
verity is assessed by a certified stroke neurologist using
the National Institutes of Health Stroke Survey (NIHSS).
The modified Rankin Scale (mRS) and the Barthel Index
(BI) serve as measures of functional outcome.
Brain MRI
Unilateral infarct localization within the anterior circula-
tion is confirmed by brain MRI. Infarcts are defined as
acute diffusion restrictions (hyperintensities) on Diffusion
weighted images with corresponding hypointense areas
on ADC maps. In addition T2-weighted and FLAIR se-
quences are acquired.
Ultrasound
Ultrasound investigations include assessment of extra-
and intracranial vessels by Doppler and color duplex
sonography. Specifically, the following measures are ob-
tained: plaque thickness, plaque localization (< 1 cm
proximal or distal to carotid bifurcation), plaque config-
uration (eccentric or concentric), echogenicity (hypo-,
iso- or hyperechoic) and stenosis grade according to
NASCET criteria.
Table 2 Schedule of assessments
Month 0 3 12 24 36
Informed consent X
Interview
Demographic variables, migration status X
Living situation and level of independence X X X X X
Vascular risk factors X
Family history (cardiovascular diseases) X
Health history (cardiovascular & neurological diseases) X
Medication X X X X X
Incident cardiovascular & neurological diseases X X X X
Neuropsychological Examinations
Montreal Cognitive Assessment (MoCA) X X
Mini Mental Status Examination (MMSE) X X
Modified Telephone Interview for Cognitive Status (TICS) X X X
Clinical Examinations
Anthropometry (Weight, Height, Waist circumference) X X
Blood pressure X X
Physical & neurological examination X X
National Institute of Health Stroke Scale (NIHSS) X X
Modified Rankin Scale (mRS) X X X X X
Barthel Index (BI) X X X X X
Technical Examinations
Blood draws for biobanking, laboratory investigations X X
electrocardiography (ECG) X X
24-hour ECG X
Screening ultrasound of the carotid arteries X
Transoesophageal and transthoracic echocardiography X
Cerebral Magnetic Resonance Imaging (MRI) X X
High resolution black blood carotid MRI (carotid MRI) X X
Contrast enhanced ultrasound (CEUS) X
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Cardiac examinations include transthoracic (TTE) and
transesophageal echocardiography (TEE), 12-lead ECG
and Holter monitoring for 24 hours. Routine TEE
includes a search for right-to-left shunt (patent for-
amen ovale), atrial septal aneurysm and intracardiac
thrombi. For research purposes the ascending aorta,
the aortic arch and the proximal portion of the de-
scending aorta is examined with respect to aortic pla-
ques, defined as irregular thickening of the vessel
wall of > 3 mm thickness [30].
Blood tests
Serum and plasma samples are taken for laboratory inves-
tigations including parameters of inflammation (e.g. hs-
CRP, interleukin), lipid status and for future analyses ofbiomarkers that will emerge during the study. Biosamples
are processed using standard operating procedures harmo-
nized with the Munich biotech cluster m4 (www.m4.de).
Stroke classification
All initial strokes and recurrent events will be classified
according to the TOAST and ASCO classification and
both classification schemes will be used for the final ana-
lyses. The Classification is carried out by two experi-
enced raters (ABK, FAW) who are blinded with regard
to the results of carotid MRI. In case of discrepancy, a
consensus will be reached by discussion.
Carotid MRI
All subjects are imaged twice (baseline and 12 month
follow up) using a multi-sequence protocol [31] (Time-
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post- contrast black-blood T1-, PD- and T2- weighted se-
quences with fat suppression; best in-plane resolution
0.5 × 0.5 mm2) at 3 Tesla (Siemens Verio, Siemens Health-
care, Erlangen, Germany) with a dedicated 4-channel sur-
face coil (Machnet B.V., Eelde, the Netherlands). Parallel
imaging is used for all sequences with a parallel acquisition
technique (PAT) acceleration factor of 2 for T1-, PD- and
T2- weighted sequences. The protocol results in a total
imaging time of 22:43 minutes for the carotid MRI.
Gadolinium-DTPA-BMA (Gadobutrol, Bayer Schering, Le-
verkusen, Germany) of 0.1 mmol/kg (0.1 ml/kg) is given at
a rate of 3 ml/s. Post-contrast T1w imaging is performed
approximately 5 minutes after intravenous injection of the
contrast agent. Fat suppression is used for pre- and post-
contrast T1w, PDw, and T2w images to reduce signals
from subcutaneous and perivascular fat. Each scan covers
30 mm (2 mm slice thickness × 15 matched images across
the 5 sequences).
Dynamic contrast-enhanced carotid MRI
In the subgroup of patients included at the coordinating
center (LMU Munich), an additional dynamic contrast-
enhanced (2D-Saturation-Recovery Spoiled Gradient Echo)
MRI series of the carotid arteries is acquired over five mi-
nutes after contrast administration consisting of two repre-
sentative axial slices with a sampling interval of 1.8 seconds
each. Using a PAT factor of 4, best in-plane resolution is
0.625 x 0.625 mm2. This sequence is acquired between the
pre- and post-contrast T1-weighted sequences. The aim of
this sub-study is to visualize markers of plaque vulnerabil-
ity, such as neovascularization and inflammation [32] and
to test whether increased plaque vascularization is associ-
ated with an increased progression rate and with a higher
rate of stroke recurrence.
18-Fluor-deoxyglucose positron emission tomography - MRI
(18 F-FDG PET/MRI)
For a subgroup of patients recruited at the Technical
University of Munich a novel, fully integrated PET/MR
system (Biograph mMR, Siemens Healthcare, Erlangen,
Germany) is used for the baseline scan. In addition to
full 3 T-MRI capabilities including the acquisition of the
aforementioned morphologic MRI-sequences, this hy-
brid PET/MR system permits the simultaneous acquisi-
tion and co-registration of a PET-dataset. To investigate
the potential increase in diagnostic information provided
by quantitative measures for the uptake of 18 F-FDG,
patients are administered approx. 5 MBq/kg body weight
of 18 F-FDG in combination with 20 mg of furosemide
via i.v. bolus injection 3 hours prior to the baseline scan.
Simultaneous acquisition of MRI-sequences and PET
data is performed in analogy to the protocols published
for cardiac imaging [33]. This additional PET-scan wasapproved by the Federal Office for Radiation Protection
(Bundesamt für Strahlenschutz, BfS). The aim of this
sub-study is to quantify plaque inflammation and to cor-
relate plaque inflammation as assessed by PET/MRI to
plaque morphology as assessed by carotid MRI. Further-
more, it will be tested whether increased plaque inflam-
mation is associated with an increased progression rate
and with a higher rate of stroke recurrence.
Contrast-enhanced ultrasound
Contrast enhanced ultrasound (CEUS) with a microbubble
based contrast agent (SonoVue®, Bracco, Italy) will be ap-
plied in a subset of patients without risk factors for ultra-
sound contrast agents. The aim of this sub-study is to
visualize markers of plaque vulnerability, such as plaque ul-
ceration or neovascularization in the intima and the plaque
[34] and to test whether increased plaque vascularization
by ultrasound is associated with an increased progression
rate by carotid MRI. Plaque vascularization will be graded
on a 4-point scale (0 = absent, 1 = little, 2 =moderate and
3 = strong). Furthermore, the origin of the neovasculature
will be recorded (1 = from the vessel wall, 2 = from the
lumen). In addition presence or absence of plaque ulcer-
ation will be recorded.
Sample size
Based on a pilot study by Freilinger et al. [24], we esti-
mated that 40% of ipsilateral carotid artery plaques in
patients with a cryptogenic stroke are complicated
AHA-LT VI plaques. Thus, in 100 patients with crypto-
genic stroke the prevalence can be assessed with a preci-
sion of +/− 10%. Our unpublished pilot data indicate a
prevalence of complicated AHA-LT VI plaques in pa-
tients with defined stroke etiology of about 10%. To de-
termine this difference with a power of 80% and 5% level
of significance, 32 patients of each group (cryptogenic
and control group) would be sufficient. Assuming a
prevalence of complicated AHA-LT VI plaques of 30%
in the cryptogenic stroke group, 64 patients in each
group are needed.
The recurrence rate of ischemic stroke associated with
complicated AHA-LT VI plaques will be determined as
the time period until the next ischemic event. Assuming
a recurrence rate of ischemic events of 8% [35] within
12 months following the index stroke and a hazard ratio
of AHA-LT VI plaques ≥ 5 [19,34,35], 300 patients will
be enough to demonstrate a significant difference in
event rates between patients with and without AHA-LT
VI plaques.
Previous longitudinal studies, which demonstrated
associations of intraplaque hemorrhage with accelerated
plaque progression and with new surface disruption,
were able to show those associations with much smaller
sample sizes [21,36]. Thus 300 patients will provide
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tures on plaque progression.
Imaging and statistical analysis
Atherosclerotic plaques in both carotid arteries (ipsilat-
eral and contralateral to the ischemic stroke) will be re-
corded and classified according to the modified criteria
of the American Heart Association [14]. Tissue compo-
nents (necrotic core, calcification, hemorrhage, loose
matrix) and type and location of hemorrhage will be
identified and quantified based on previously published
criteria [15,36]. For definition of a complicated AHA-
LT-VI plaque, at least one of the following three criteria
is required: fibrous cap rupture, intraplaque hemorrhage,
juxtaluminal hemorrhage/mural thrombus (see Figure 1
for an example of a complicated AHA-LT VI). Area
measurements of the lumen, outer wall, and tissue com-
ponents are obtained using the custom-designed image
analysis tool CASCADE (University of Washington, Se-
attle, US) [37].
All carotid and brain MRI examinations will be evalu-
ated by two radiologists blinded to the clinical status. In
case of discordant results, a consensus decision will be
made. Image quality is rated on a five point scale (1 =
worst, 5 = best), with MRIs ≥3 included for further ana-
lysis [31].
New ischemic lesions on brain MRI during follow up
are defined as hyperintense lesions clearly visible on T2
weighted sequences.
All statistical analyses will be performed using SPSS
and SAS. For determination of differences in prevalence
of complicated AHA-LT VI plaques between patientsFigure 1 Axial images of specific AHA-LT VI plaque features in a patie
the carotid arteries demonstrate a large eccentric plaque with <50% steno
sequences consistent with fresh intraplaque hemorrhage (A, arrow). Axial im
plaque, which is hypo- to isointense on T1w + CM, PDw and TOF, consisten
sequence, PDw: PD-weighted sequences, T2w: T2-weighted sequence, TOF
sequence after contrast administration).with cryptogenic stroke and stroke with defined etiology
the Chi square test will be used. Differences in the
prevalence of complicated AHA-LT VI plaques ipsi- and
contralateral to the ischemic stroke will be calculated
using the McNemar Test. For the cross-sectional ana-
lysis the prevalence of AHA-LT VI plaques in patients
with territorial infarcts, multiple embolic infarcts and
small lacunar lesions will be compared. Furthermore, the
difference in prevalence of AHA-LT VI plaques in pa-
tients with aortic arch plaques < 3 mm and > 3 mm will
be determined. Data from the serial plaque study are an-
alyzed in accordance to previous studies [38]. The effect
of plaque morphology on cerebrovascular (TIA, amaur-
osis fugax and stroke) and cardiovascular events (myo-
cardial infarction, vascular death) will be assessed using
Cox proportional-hazards regression analysis. Cohen’s
kappa test will be employed to evaluate the intra- and
inter-reader agreement for identification of AHA-LT VI.
For distinctions of the stroke subtypes regarding recur-
rence rates of cerebrovascular events, Kaplan-Meier curves
and Cox regression analysis will be used. For categorical
variables, Fisher’s exact test and for continuous variables,
an unpaired t-test will be applied. All p-values <0.05 will
be considered as statistically significant.
Discussion
This study differs from previous carotid plaque imaging
studies in several ways. First, we focus on patients with
cryptogenic stroke, classified by two raters and exclude
patients with high grade stenosis (>70%), who usually
undergo immediate invasive treatment and cannot be
followed regarding plaque progression. Second, mostnt with acute ischemic infarct. High-resolution black blood MRI of
sis in the right carotid artery, hyperintense on T1w, T2w and PDw
ages 0.6 cm above the bifurcation show an area attached to the
t with a mural thrombus (B, arrow). (T1w: T1-weighted black blood
: Time-of-flight MR angiography, T1w + CM: T1-weighted black blood
Table 3 Baseline characteristics of the first 79 patients
enrolled in Munich
Age in years (median, Q1-Q3) 74 (68–83)
Female (n,%) 25 (32)
Systolic blood pressure at admission (mean, SD) 142 (19)
Diastolic blood pressure at admission (mean, SD) 78 (11)
BMI (mean, SD) 26 (3)
Pre stroke living condition (n,%)
At home alone 23 (32)
At home with family or friends 46 (64)
Institutionalized 2 (3)




mRS on admission (n,%)
0–2 47 (60)
3-5 31 (40)






MoCA (median, Q1-Q3) 26 (23–28)
Baseline medication (n,%)
Antiplatelet therapy 30 (38)
Statin 30 (38)
Oral anticoagulation 8 (10)
Ischemic Subtype (n,%)
Large artery atherosclerosis 11 (14)
Cardioembolism 21 (27)
Small vessel occlusion 10 (13)
Other causes 0
Multiple potential causes 4 (5)
Cryptogenic 32 (40)
Incomplete assessment 1(1)
Cardiovascular Risk Factors (n,%)
Coronary artery disease 17 (22)
Peripheral artery disease 10 (13)
Arterial hypertension 57 (72)
Smoking 39 (49)
Diabetes mellitus 17 (22)
Hypercholesterolemia 22 (28)
Atrial fibrillation 10 (13)
Data are given as medians (interquartile range), means (SD), and frequencies
(percentages). BMI indicates body mass index; NIHSS, National Institute of
Health Stroke Scale; mRS, modified Rankin Scale; BI, Barthel Index and MoCA,
Montreal Cognitive Assessment.
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index event, including not only patients with a stroke
documented by DWI-positive lesions on brain MRI, but
also patients with TIA and amaurosis fugax [16,19], or
even focused on asymptomatic patients [20,22]. Third,
the time interval between the event and the MRI scan
was up to 3 months [23], whereas CAPIAS includes
patients within 7 days after symptom onset. Histopatho-
logical studies have shown that plaque features associ-
ated with vulnerability have the highest frequency in the
first days after the ischemic event, thus suggesting that
a short time period between event and MRI seems to
be preferable [6,39]. Furthermore we excluded stroke
patients younger than 50 years because the etiologic
spectrum in this group differs from that in older sub-
jects. The most frequent etiologic subgroups in the age
range of 16–49 years are cardioembolism and arterial
dissections while strokes due to large-artery atheroscler-
osis are extremely rare [40]. Finally, patients are system-
atically followed by clinical examination for 36 months
and brain MRI for 12 months. Recent results of rela-
tively small studies suggested that with improvement in
best medical treatment the rate of recurrent events has
decreased substantially in recent years. However, to date
no larger trials are available which show the exact rate
of recurrent events in ischemic stroke patients with
<70% carotid artery stenosis and >2 mm atherosclerotic
plaques and therefore it is impossible to provide precise
estimates of the rate of stroke recurrence. In order to
improve the power of the study we will use a clinical fol-
low up period of 36 months and we will count silent is-
chemic lesions in the 12 months follow up brain MRI.
Furthermore we will collect the number of TIA, amaur-
osis fugax and cardiovascular events.
This study also has limitations. Secondary prevention
during follow up will differ among study participants
depending on previous medication and stroke etiology.
Patients with LAA or SVD are treated with antiplatelet
agents, whereas patients with a cardioembolic etiology
usually receive anticoagulants. Also, this study offers no
information on the natural history of carotid plaques as
all patients receive statin treatment for secondary stroke
prevention. As demonstrated in several studies, statins
influence the development of plaque burden, intraplaque
hemorrhage and inflammation [39]. Another limitation
is the additional scan time of the study-related MRI
protocol, which may result in movement artifacts and
severely affected stroke patients may refuse receiving an
additional MRI.
So far, clinical and radiological baseline data of 79 pa-
tients have been analyzed. Stroke subtyping using the
TOAST criteria showed the following distribution: 14%
of subjects had LAA, 27% had CE, 13% had SVD, 5%
had multiple potential causes (MPC) and 40% had
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with LAA, the absence of other stroke causes and the high
percentage of cryptogenic stroke result from our inclusion
and exclusion criteria. Thus, the number of patients with
LAA is smaller than expected as patients with ≥ 70% sten-
osis are excluded. Furthermore, we only include patients
with advanced atherosclerotic disease, defined as plaques ≥
2 mm in the carotid arteries, which might also explain the
smaller than expected%-ages of patients with CE and SVD
and the absence of patient with other stroke causes e.g. ca-
rotid artery dissection. Consistent with this notion, pa-
tients with cryptogenic stroke compromised almost half of
our patient population, suggesting a potential link between
atherosclerotic disease and the underlying cause of the is-
chemic stroke.
An initial analysis of primary endpoint data showed a
significantly higher prevalence of complicated AHA-LT VI
plaques in cryptogenic stroke patients ipsilateral (37%)
than contralateral (3%) to the ischemic stroke (p < 0.0001,
McNemar). These preliminary results are in accordance
with our pilot study suggesting a high prevalence of com-
plicated AHA-LT VI plaques in the ipsilateral carotid ar-
tery in patients with cryptogenic stroke and unilateral
anterior circulation infarcts. If confirmed in the entire
cohort, our findings may have important implications for
the understanding of stroke mechanisms. Moreover, this
study might offer new diagnostic options by using high-
resolution black-blood carotid MRI in the identification
of risk patients for arterio-arterial embolism, as demon-
strated in our first case report [41]. The question if these
patients should receive a more aggressive or even inter-
ventional treatment has not been answered yet. Thus, we
think that the results of our study could provide the basis
for the planning of targeted interventional studies.
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